Last reviewed · How we verify
LY2875358
At a glance
| Generic name | LY2875358 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (PHASE2)
- A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer (PHASE1, PHASE2)
- A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants (PHASE2)
- A Study of LY2875358 in Participants With Advanced Cancer (PHASE1)
- A Study of LY2875358 in Japanese Participants With Advanced Cancer (PHASE1)
- A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2875358 CI brief — competitive landscape report
- LY2875358 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI